Retatrutide
100% delivery
- Satisfaction Guaranteed
- No Hassle Refunds
- Secure Payments
Description
Retatrutide
RETA · LY3437943 · LY-3437943

Retatrutide (RETA; LY3437943) is a synthetic 39-amino-acid peptide with agonist activity at the glucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), supplied for laboratory research.(RTS,RETA,LY3437943)
Overview
Retatrutide is a 39 amino acid single peptide engineered from a GIP peptide backbone. It is fatty-acid acylated and combines GCGR, GIPR and GLP-1R activities in one chain.
LeadePeptide supplies retatrutide with full analytical documentation, scalable quantities and dependable worldwide delivery.
What is Retatrutide?
Retatrutide is a single 39-residue peptide. The backbone carries three non-coded residues: Aib at positions 2 and 20, and α-methyl-L-leucine at position 13. Aib2 is used against DPP-4 cleavage. A C20 fatty diacid is attached through a linker at the lysine at position 17. The C-terminus is a serinamide.
Receptor pharmacology
In published cell assays, retatrutide is a full agonist at GCGR, GIPR and GLP-1R. Relative to the native ligands, potency was reported as 8.9-fold higher at human GIPR, about 0.4-fold at GLP-1R and about 0.3-fold at GCGR. The in vitro profile is therefore GIPR-forward, with lower relative activity at GLP-1R and GCGR.
Characterization
Each batch is HPLC-purified and mass-confirmed, with identity, purity and net peptide content documented on the COA.
Key Highlights
- Triple agonist at GCGR, GIPR and GLP-1R
- 39-amino-acid GIP-backbone peptide; Aib2, Aib20, αMeL13
- C20 fatty diacid at Lys17 (albumin-binding motif in the published structure)
- ≥99% purity verified by HPLC & Mass Spectrometry
- Lyophilized solid peptide, good stability
- Full batch-to-batch traceability, COA available for every lot
- Third-party tested, research-grade raw material
Safety & Side Effects
Retatrutide (RETA; LY3437943) is a synthetic 39-amino-acid peptide with agonist activity at the glucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), supplied for laboratory research.(RTS,RETA,LY3437943) When used in research, Retatrutide should be handled in a qualified laboratory setting, and its safety profile should be interpreted strictly within the experimental context in which it was studied.
Published retatrutide side effects data are limited to experimental models and are specific to the dose, route, and study design employed. Investigators should account for metabolic regulation and energy expenditure readouts and any off-target effects relevant to the compound’s mechanism when designing a study.
For authoritative safety and toxicology references, consult peer-reviewed databases (PubMed, PubChem) and review the batch Certificate of Analysis before designing your protocol.
Dosage & Protocol
There is no standardized human dosage for Retatrutide; it is supplied strictly for laboratory research. Reported retatrutide dosage values in the literature are derived from preclinical studies and are specific to the study model, route, and experimental design.
Research protocols typically document retatrutide dosage together with reconstitution method, storage conditions, and analytical confirmation of identity (CAS 2381089-83-2, molecular formula C221H342N46O68, molecular weight 4731.33 g/mol). Because dose-response relationships may not scale across models, investigators should base their design on peer-reviewed methods rather than informal community reports.
Always confirm the exact strength, purity, and lot-specific data from the batch COA before weighing or reconstituting your sample.
Comparison
| Peptide | Receptors | Core Characteristic |
|---|---|---|
| Retatrutide(RETA) | GLP‑1R+GIPR+GCGR | Triple agonist for metabolic research |
| Tirzepatide | GLP‑1R+GIPR | Dual‑receptor metabolic peptide |
| Semaglutide | GLP‑1R | Single GLP‑1 receptor agonist |
How to Order
Enquiry
Send strength and quantity for a quote.
Quotation
Price, lead time and specification confirmed.
QC & COA
HPLC/LC-MS tested; COA issued.
Delivery
Tracked worldwide shipping.
Specifications
| Product name | Retatrutide |
|---|---|
| Product code | RT5 |
| Specification | 5mg*10vials |
| CAS number | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731.33 g/mol |
| Purity | ≥99% (subject to batch COA) |
| Physical Form | Lyophilized white solid powder |
| Solubility | Soluble in bacteriostatic water |
| Amino Acid Count | 39 residues |
Applications
Packaging & Shipping
Available pack sizes
Shipping
Storage & Handling
Store lyophilized at −20 °C, protected from light and moisture. Bring to room temperature before opening. Refrigerate after reconstitution and avoid repeated freeze–thaw cycles.
Product Information Q&A
Is Retatrutide third‑party tested?
Yes, every batch is third‑party tested for purity verification.
Can I view the Certificate of Analysis before purchase?
Corresponding batch COA documents are available upon request.
What does “Research Use Only” mean?
This peptide is for laboratory research only, not for human or veterinary administration.
How should Retatrutide be shipped and stored?
Shipped as lyophilized powder. Store dry powder at‑20℃ away from light and humidity.
Which receptors does retatrutide engage?
Published assays report agonist activity at GCGR, GIPR and GLP-1R. In vitro potency was higher at GIPR than at GLP-1R or GCGR relative to the native ligands.
What is the sequence length of retatrutide?
It is a 39-amino-acid single chain with Aib at positions 2 and 20, α-methyl-L-leucine at position 13, and a C20 fatty diacid at Lys17; the C-terminus is a serinamide.
Additional information
| Specification | 5mg*10vials, 10mg*10vials, 15mg*10vials, 20mg*10vials, 30mg*10vials, 40mg*10vials, 50mg*10vials, 60mg*10vials |
|---|






